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Background Some countries have banned the sale of electronic nicotine delivery systems (ENDS). 
Aims We analyse the ethical issues raised by this ban and various ways in which the sale of ENDS 
could be permitted. 
Method We examine the ban and alternative policies in terms of the degree to which they respect 
ethical principles of autonomy, beneficence, non-maleficence and justice, as follows. 
Results Respect for autonomy: prohibiting ENDS infringes on smokers’ autonomy to use a less 
harmful nicotine product while inconsistently allowing individuals to begin and continue smoking 
cigarettes. Non-maleficence: prohibition is supposed to prevent ENDS recruiting new smokers and 
discouraging smokers from quitting, but it has not prevented uptake of ENDS. It also perpetuates 
harm by preventing addicted smokers from using a less harmful nicotine product. Beneficence: ENDS 
could benefit addicted smokers by reducing their health risks if they use them to quit and do not 
engage in dual use. Distributive justice: lack of access to ENDS disadvantages smokers who want to 
reduce their health risks. Different national policies create inequalities in the availability of products 
to smokers internationally. 
Conclusions We do not have to choose between a ban and an unregulated free market. We can 
ethically allow ENDS to be sold in ways that allow smokers to reduce the harms of smoking while 
minimizing the risks of deterring quitting and increasing smoking among youth. 
  
Introduction 
During the past 30 years developed countries at the forefront of tobacco control have reduced 
smoking prevalence very substantially to approximately 15% [1] by: imposing higher tobacco taxes; 
banning cigarette advertising; introducing smoke-free policies in all public spaces and work-places; 
graphic health warnings; and plain packaging of cigarettes [1-3]. 
 
The persistence of smoking in a substantial minority of adults [4, 5] has prompted some public 
health researchers to advocate for ‘tobacco harm reduction’ (THR) [6-8]. THR policies encourage 
smokers who do not want to quit, or are unable to do so, to obtain their nicotine in ways that do not 
involve smoking cigarettes [9]. Electronic Nicotine Delivery Systems (ENDS) have been the most 
controversial of the products advocated for THR [7, 8, 10]—which also include pharmaceutical 
nicotine [9], and the low nitrosamine smokeless tobacco product, snus [11, 12]. 
 
All ENDS deliver nicotine in an aerosol that is inhaled and produces effects that smokers report feel 
more like smoking than nicotine replacement therapies (NRTs). The short-term health effects of 
ENDS when used for smoking cessation are minor, because the carcinogens and toxicants in the 
aerosol occur at much lower levels than in tobacco smoke [13, 14]. This has been confirmed by 
urinary analyses of ENDS users’ and smokers’ exposures to toxicants and carcinogens [15]. The 
adverse effects of long-term use of ENDS are unknown, but are likely to be substantially less than 
those of daily cigarette smoking [13, 16]. 
 
In this paper, we focus on the ethical issues raised by bans on the sale of ENDS that apply in 13 of 59 
countries that regulate ENDS [17]. Leading international public health advocates have expressed 
support for sales bans [18]. In Australia, for example, sale and possession or use of ENDS containing 
nicotine for non-therapeutic purposes is banned under drugs and poisons legislation. Possession and 
use for therapeutic purposes is only legal with a medical prescription [19]. In future, ENDS could be 
sold as smoking cessation aids if they are approved by pharmaceutical regulatory authorities, but 
none have been. 
 
In market economies, companies and individuals have a right to manufacture and sell products, 
unless governments have a good reason to ban them. The current sales ban on ENDS reflects a policy 
of prohibiting new non-medicinal psychoactive substances, a position some governments are 
attempting to move away from [20]. In the case of ENDS, the extraction of nicotine from tobacco is 
not new, but its use in ENDS for non-medicinal purposes is. However, the use of much more 
dangerous tobacco cigarettes is not banned. 
Arguments for and Against Allowing the Sale of Ends 
 
THR advocates [21] argue that huge public health gains can be made if all current smokers switch to 
ENDS because their health risks are perhaps only 10% of those caused by cigarette smoking [22]. 
These gains would be achieved either if smokers use ENDS to quit, or they use ENDS as a long-term 
alternative to smoking cigarettes (e.g. [23]). 
 
Those who favour a ban on ENDS do not believe that their use will produce public health benefits. 
Instead of helping smokers to quit smoking, they believe that smokers who use ENDS will continue 
to smoke and that this ‘dual use’ will have no health benefits. They would allow the use of ENDS for 
smoking cessation only if they are shown to be safe and effective for this purpose, and if they were 
approved by pharmaceutical regulatory authorities. 
 
Critics of ENDS are opposed to them being sold in the same way as cigarettes [24-29] because they 
are convinced that the tobacco industry will use ENDS to: (1) discourage smokers from quitting, by 
encouraging dual use (i.e. using ENDS when smoking is not allowed and continuing to smoke when it 
is) and thereby undermine smoking bans; (2) re-normalize and glamourize a behaviour that 
resembles smoking; and (3) provide a gateway to smoking among young adults. Their fears have 
been heightened by the fact that multi-national tobacco companies have purchased leading ENDS 
producers [25]. 
 
An ethical appraisal of the ENDS debate 
 
In pluralistic democracies there is rarely unanimous agreement on how to resolve conflicts between 
competing normative or ethical views such as those raised by ENDS. Ethical analyses of these issues 
rarely command universal assent. Advocates of different ethical theories offer advice on which 
course of action ought to be pursued [30, 31]. These include: utilitarianism or consequentialism, 
which judges individual actions or moral rules by the net effects for good and ill that they have on all 
who are affected by them (e.g. [32]); deontological or duty-based theories that derive obligatory 
rules for moral conduct from general ethical principles (e.g. [33, 34]); and rights-based theories [31, 
35]. 
 
In the face of major disagreements about these different ethical theories, bioethicists have often 
used four influential moral principles (principlism) to analyse and frame debates about ethical issues 
in medicine and public health. Autonomy, non-maleficence, beneficence and justice are four clusters 
of moral principles that derive from a common morality, ethical principles often shared by people 
who support very different ethical theories [31]. These principles have been invoked in debates over 
ENDS. We use this approach to identify possible policy compromises that may attract majority 
support for politically acceptable trade-offs between these competing ethical principles. 
 
Respect for autonomy 
 
We respect autonomy when we do not interfere with the free and informed choices of rational 
adults [31]. Most ethical theories assume that rational people have the capacity to decide freely 
upon the course of action that they judge to be in their own best interests. Most theories would 
agree that we should not interfere in the exercise of autonomy by rational adults, e.g. by coercing 
them into behaving in a certain way, or encouraging them to act in ways that we think are in their 
best interests by providing false or misleading information. 
 
There is disagreement about whether individuals decide autonomously to consume nicotine, either 
in the form of cigarettes or ENDS. Individuals are currently free to begin and to continue smoking 
cigarettes but, in countries where ENDS are banned, they are prevented from consuming nicotine in 




The principle of non-maleficence means that we should ‘do no harm’. It generally requires us to 
refrain from acting in ways that will cause harm or injury to others, or that place others at risk of 
harm or injury. The challenge in applying this principle is that few, if any actions, are guaranteed to 
be harm free. Policymaking usually involves a choice between policies that produce a mix of harms 
and benefits, rather than selecting a policy that causes no harm. 
 
Much of the discussion around ENDS focuses upon their aggregate effects on two types of harm: (1) 
the health risks for current smokers who may be by helped to quit or reduce the harms of nicotine 
use; and (2) tobacco-related harm that may be increased if ENDS discourage smokers from quitting 




Beauchamp & Childress [31] have identified ‘positive beneficence’ and ‘utility’ as two elements of 
beneficence. Positive beneficence requires us to perform actions that benefit others. Utilitarian 
approaches to beneficence aim to maximize utility (or pleasure) by ensuring that the aggregate 
benefits of policies outweigh the costs incurred by all people who are affected by the policy. This 
involves aggregating the benefits and costs in the population across different types of individual, e.g. 
current smokers and possible future smokers. 
 
Beneficent regulation of ENDS will depend upon whether regulators see their goal as fostering 
choice and reducing harm from smoking or eliminating all nicotine use. As we will explain below, 
ENDS provide significant advantages to smokers who are willing to switch but may pose risks to 
newly recruited smokers. 
Distributive justice 
 
‘Distributive justice’ requires policies to be fair in the ways that they treat everyone affected by 
them. This involves fairly sharing the resources, risks and benefits of different public health policies. 
Bans on ENDS raise issues of equity by disadvantaging smokers who want to reduce the health risks 
of using nicotine. Different national policies towards ENDS may create inequalities in access between 
smokers in different countries. 
 
Resolving conflicts between ethical principles 
 
In pluralistic liberal democracies, ethical conflicts arising in public health policy debates are resolved 
by the political system which produces legislative and regulatory responses. These responses enact 
consensus, when one exists, but more often reflect negotiated compromises that are acceptable to 
most members of the community. These compromises rarely involve a simple comparison of the 
costs and benefits of different policy options. Policy choices more often involve complex 
comparisons of different types of costs and benefits, many of which are difficult to quantify, in the 
absence of consensus on the relative weighting that should be attached to these competing values. 
 
In debates about public health policy, the principles of autonomy and beneficence conflict when 
policies, such as a sales ban, infringe the autonomy of adults to act in ways that may harm 
themselves in order to protect the health of individuals and the whole population. For example, in 
most developed countries, criminal law denies adults the right to use heroin and cocaine in order to 
prevent addiction, fatal overdoses and blood-borne virus infections. 
 
Our approach to analysing the ethical issues raised by ENDS is pragmatic. We evaluate the ethical 
implications of two broad policy options: retaining a ban on the sale of ENDS; and two very different 
ways of allowing ENDS to be sold. 
 





Libertarians oppose bans on the sale of ENDS [36] because they do not believe that they respect the 
autonomy of adult smokers. In their view, smokers should be allowed to purchase ENDS as easily as 
cigarettes. One need not be a libertarian to believe that a ban on ENDS sales seriously infringes 
smokers’ autonomy and that such infringements require a strong justification. 
 
Tobacco control advocates often respond to libertarian arguments by arguing that smokers’ choices 
are not autonomous because of their addiction. Whatever its merits, they selectively invoke this 
argument by using it to justify a ban only on ENDS and still allow smokers to exercise their impaired 
autonomy by purchasing cigarettes. Any argument in favour of a ban on ENDS based on an appeal to 
smokers’ impaired autonomy would also logically entail supporting a ban on the sale of cigarettes, 
which are much more dangerous than ENDS. 
Non-maleficence and beneficence 
 
Disagreements about the net harms and benefits of ENDS are at the centre of the debate about bans 
on ENDS sales. Proponents of ENDS emphasize the potential health benefits for current smokers 
who switch to ENDS. Proponents of the ban are sceptical that these benefits will be realized for 
smokers and concerned about potential harms to future smokers. 
 
Proponents of the ban on ENDS give a low priority to smoker autonomy and a high priority to 
beneficence by protecting public health. The interests of current smokers are given very little weight 
by those who support a ban on ENDS sales. They may want to argue that a sales ban serves smokers’ 
interests by encouraging them to quit. They sometimes argue that ENDS are not as harmless as their 
proponents claim [10], in the process engaging in what critics of the ban claim is a misrepresentation 
of the evidence on the toxicology of ENDS vapour [37]. 
 
Proponents of a ban argue that it benefits public health by preventing the initiation of new smokers, 
especially adolescents. Allowing ENDS to be sold, in their view, will increase the number of new 
smokers: by re-normalizing a behaviour that resembles smoking; increasing uptake of ENDS by 
adolescents who would not otherwise smoke; and serving as a gateway to smoking among a 
substantial proportion of adolescent ENDS users. They claim to have evidence that this is happening 
in surveys of ENDS use by US youth, among whom substantial proportions of people who have ever 
used ENDS had never smoked a cigarette [38]. 
 
Proponents of allowing ENDS sales give a high priority to reducing the harms of smoking among 
current smokers who are unable or unwilling to quit. In their view, a ban on sales prevents smokers 
from using ENDS to quit or to replace cigarette smoking by effectively forcing them to quit, if they 
can, and to smoke cigarettes, if they cannot. A ban has other adverse effects: it produces a black 
market for ENDS and it prevents ENDS products from being regulated to protect consumers, e.g. by 
ensuring that they deliver nicotine safely and protect children from nicotine poisoning. 
 
Proponents of ENDS reject the claim that ENDS will re-normalize smoking and serve as a gateway to 
smoking. They criticize the Centers for Disease Control (USA) for confusing ever having used ENDS 
with regular use [37], and they cite UK survey data that ENDS are used by fewer than 1% of people 
who have never smoked cigarettes [39]. They also cite evidence that smoking prevalence has 
declined in the United Kingdom as a whole, and among youth, over the same time-period that ENDS 
use has increased among current and former UK smokers [37]. 
Justice and fairness 
 
A policy that bans a less harmful form of nicotine while allowing the sale of cigarettes is inconsistent. 
This makes it difficult to justify. It is also unfair to addicted smokers who are denied access to a safer 
nicotine product and forced to continue to smoke cigarettes. It is also arguably unjust in giving a 
much higher priority to the interests of hypothetical future smokers at the expense of the interests 
of current, especially addicted, smokers. 
Ethical issues raised by allowing the sale of ENDS 
 
A policy that allows smokers to buy ENDS respects their autonomy. It does not inconsistently 
prohibit the use of a less harmful nicotine product while allowing the sale of the most harmful, 
tobacco cigarettes. Allowing smokers to use ENDS also benefits those smokers who quit or wholly 
switch to ENDS. It would also reduce the size of a black market and allow better regulation of ENDS 
products. 
 
The critical question for advocates of allowing ENDS sales is: how can we allow smokers to buy ENDS 
in ways that minimize the public health risks of most concern to those who support a sales ban? We 
explore this question by considering the ethical issues raised by different ways in which smokers 
could be allowed to access ENDS. 
 
ENDS for medical use only 
 
Under the ban discussed above, ENDS will be available to smokers only as medicinal products for 
smoking cessation, if clinical trials show them to be safe and effective, and if they are approved for 
use as therapeutic goods. This policy is ethically problematic for two reasons. First, it is not clear how 
many ENDS manufacturers will have the funds required to have their products registered as 
cessation aids. This requirement may effectively confine approved ENDS products to those owned by 
the tobacco industry. Secondly, a ban does not allow smokers who want to use ENDS from doing so 
before the pharmaceutical approval process has been completed. Until these products are 
approved, smokers who want to use ENDS must obtain them from an unregulated black market. 
Thirdly, limiting ENDS availability to prescription only is paternalistic in requiring medical approval 
for use of a product that is used in much the same way as cigarettes, which are sold legally. 
Allowing ENDS to compete with tobacco cigarettes 
 
Conceptually, there are two ways in which ENDS could be allowed to compete with cigarettes: 
‘levelling up’ and ‘levelling down’ [40]. 
 
Levelling up would allow ENDS to be sold in the same way and at the same places as cigarettes (e.g. 
supermarkets, convenience stores, tobacconists). ENDS could be taxed at the same rate as cigarettes 
or taxed at a lower rate because they are less harmful than cigarettes. This would mean that ENDS 
would be regulated as lightly as cigarettes are now. 
 
Levelling up is the preferred approach of advocates who want ENDS to replace cigarettes as quickly 
as possible. It also respects smoker autonomy, is fairer to addicted smokers and is consistent in 
allowing smokers to access a safer form of nicotine as easily as cigarettes [41]. Opponents of ENDS 
see levelling up as the approach most likely to increase ENDS uptake among non-smokers and to 
recruit new cigarette smokers. 
 
Levelling down would increase restrictions on both the sale of tobacco cigarettes and ENDS. It would 
restrict sales of both products to a limited number of licensed sellers. It could include bans on 
advertising and promotion of ENDS and on their use in public spaces. A very restrictive variant of this 
policy would allow ENDS to be sold only by licensed suppliers to licensed users [42]. 
 
Levelling down is much less likely than levelling up to produce the adverse public health effects 
feared by proponents of a ban on ENDS. It is also consistent in allowing smokers to access both ENDS 
and tobacco cigarettes. It is mildly paternalistic in not allowing smokers to access ENDS as easily as 
they can buy cigarettes. 
 
The Unavoidability of Ethical Trade-Offs 
 
Any policy towards ENDS unavoidably involves trade-offs between respecting autonomy, 
beneficence, non-maleficence and fairness. These trade-offs have to be made in the face of some 
uncertainty about the future aggregate costs and benefits of either retaining a sales ban or allowing 
ENDS to be sold to smokers. These competing views about the ethics and public health 
consequences of banning or allowing ENDS sales are summarized in Table 1. 
 
Table 1. Competing ethical appraisals of those who support banning and permitting electronic 
nicotine delivery systems (ENDS) to be sold. 
  Ban ENDS sales Permit ENDS sales 
Pro ban Avoids increasing harm 
from: 
Risks increasing harm by: 
Allowing dual use Deterring quitting 
Re-normalizing smoking Re-normalizing smoking 
Recruiting new smokers Recruiting new smokers 
Long-term vaping Encouraging long-term vaping 
Con ban Over-rides smoker 
autonomy 
Respects smoker autonomy 
Inconsistent in regulating 
risks 
Consistent policy on risks 
Unfair to addicted smokers Fair to addicted smokers 
Produces a black market 
for ENDS 
Avoids black market in ENDS 
Fails to regulate ENDS Allows ENDS to be regulated 
 
 
A sales ban on ENDS over-rides smokers’ autonomy in order to protect public health against the 
projected long-term effects of ENDS on smoking recruitment. It is unjust to smokers who wish to 
reduce the harms of consuming nicotine. It is inconsistent in forbidding the use of less harmful 
nicotine products while allowing the unregulated sale of the most harmful, cigarettes. It also fails to 
regulate ENDS while allowing a black market to grow. Advocates of a ban would argue that these are 
acceptable costs to avoid undermining successful tobacco control policies and prevent the 
recruitment of new cigarette smokers. 
 
Policies that would allow ENDS to be sold are more respectful of smokers’ autonomy and fairer to 
smokers. They will reduce harm for those smokers who use ENDS to quit smoking or who switch 
completely from smoking to ENDS. The cost of securing these benefits is that we allow the 
recreational use of ENDS. The net effects of this policy on public health will depend upon how 
restrictive the regulations are on the ways in which ENDS can be sold. 
 
The logically possible ways in which ENDS sales could be regulated suggest that levelling down 
approaches (1) may be more acceptable to advocates and opponents of THR using ENDS and (2) will 
make it easier to assess the public health consequences of allowing smokers to use ENDS. 
 
The Need for Policy Evaluation 
 
If a ban on sales becomes the standard response to ENDS in most countries it will be more difficult 
to evaluate their impact. Research on ENDS use under a global sales ban will encounter many of the 
same problems that arise in research on illicit drug use, drug-related harm [43] and the effectiveness 
of different illicit drug policies [44]. 
 
The Australian ban, for example, has made it difficult to conduct trials on the potential use of ENDS 
for harm reduction because they must be evaluated as smoking cessation devices, rather than as a 
less harmful competitor to cigarettes. The regulatory restrictions on ENDS have also limited the 
products that can be given to smokers. 
 
Why Not Wait? 
 
Supporters of the bans may suggest that countries with bans should retain them until studies have 
been conducted on the public health outcomes of ENDS in countries that allow their sale. This would 
allow countries that impose bans to avoid the risk of ENDS products in their own countries. 
 
We see several problems with this proposal. First, it will take a decade or more before we know the 
outcome of the policy. During this time smokers will be denied access to a safer form of nicotine. 
Secondly, we doubt that any epidemiological evidence would be strong enough to change the minds 
of those who support a ban. Pre-emptive bans on the sale of low nitrosamine smokeless tobacco 
(snus) in Australia and the European Union remain in place, despite 20 years of epidemiological 
evidence showing that snus reduces harm to smokers and has not increased smoking among youth 
[45]. Advocates of a ban, and those who propose to wait, have an ethical obligation to specify what 
type of evidence would convince them to lift a ban on ENDS sales. Thirdly, a ban has not prevented 
ENDS use by smokers in Australia and other countries; it has abdicated responsibility for regulation 
of ENDS to the black market [46]. It has also not prevented child poisonings from ENDS, which could 
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